

For chemotherapy-induced anemia

Fewer stops to your Hb destination



Aranesp® helps achieve anemia treatment goal with fewer injections than Epoetin alfa*

- Less frequent injections for fewer hassles—due to an approximately 3-fold longer half-life, Aranesp® should be administered less frequently than Epoetin alfa,* resulting in fewer trips to the office for injections
- Provides a sustained erythropoietic effect to reach and maintain anemia treatment goal¹—target Hb ≤ 12 g/dL
- New—Aranesp® SingleJect® prefilled syringes save preparation time

 **Aranesp®**
(darbepoetin alfa)

Aranesp® is indicated for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies.

Aranesp® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of thrombotic and other serious events; dose reductions are recommended if the hemoglobin increase exceeds 1.0 g/dL in any 2-week period. The most commonly reported side effects in Aranesp® trials were fatigue, edema, nausea, vomiting, diarrhea, fever, and dyspnea.

*For example, where Epoetin alfa is administered three times a week, Aranesp® should be administered weekly.²

References: 1. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized, phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. *J Natl Cancer Inst.* 2002;94:1211-1220. 2. Aranesp® (darbepoetin alfa) full prescribing information, Amgen.

Please refer to the accompanying brief summary of the Aranesp® prescribing information.

© 2003 Amgen. All rights reserved. MC20610-A 08-03